EBS
Emergent BioSolutions Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
7.22
close · 2026-10-29
value
96
cheaper than peers96
quality
22
stronger fundamentals22
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| EV to EBITDA | 4.89× | 91 |
| price to book | 1.08× | 90 |
| forward P/E | 6.90× | 83 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -1.6% | 54 |
| operating margin | 6.8% | 49 |
| debt to equity | 111.8% | 36 |
| revenue growth | -29.7% | 12 |
4 of 4 measures available
Facts
| market cap | $370M |
| free cash flow | $256.2M |
| employees | 900 |
| first trade | 2006-11-15 |
| next earnings | 2026-11-02 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.93 | -3.60 | -14.85 | -4.47 |
| free cash flow | $156.8M | $35.8M | -$257.9M | -$149.9M |
| net income | $52.6M | -$190.6M | -$760.5M | -$211.6M |
| revenue | $705.2M | $1.01B | $1.02B | $1.08B |
| unusual items | -$24.4M | -$2.3M | -$448.2M | -$6.7M |